Biosergen AS: Funding, Investors & Team (Sep 2026)
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.
Biosergen AS has raised $4.1M across 1 funding round on record, the most recent an undisclosed round of $4.1M announced in Nov 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Biosergen AS Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Biosergen AS Funding Rounds
Biosergen AS Founders and Leadership Team
No contact details are on record for this team yet.
Biosergen AS Funding Compared to Other Biotechnology Startups
Biosergen AS' latest round of $4.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Biosergen AS in Biotechnology and Trondheim
Companies Similar to Biosergen AS
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on…
Hofseth BioCare's key goal is to offer high benefit added biomarine elements for human applications. Through…
Circio Holding ASA is a company in the clinical stage that is developing immune activators for challenging…
IDEX, a biometrics software and fingerprint authentication company based in Oslo, Norway, was established in…
Arctic Bioscience is a biotechnology research company that develops products, solutions, and technologies…
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer…
Actithera is a company specializing in developing radioligand therapies through the application of medicinal…
NoMy is a company focused on creating sustainable and scalable solutions for alternative proteins by…
Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of…
NEXT offers secure and user-friendly fingerprint sensor technology for verification purposes in various…
We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who…
Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These…
Biosergen AS Funding FAQs
What does Biosergen AS do?
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.
How much funding has Biosergen AS raised?
Biosergen AS has raised $4.1M across 1 round on record. The most recent is an undisclosed round of $4.1M announced in Nov 2024.
When did Biosergen AS last raise funding?
Biosergen AS' most recent funding round on record is an undisclosed round of $4.1M, announced in Nov 2024.
Who founded Biosergen AS?
FundedIQ lists Peder M Andersen (Founder) at Biosergen AS.
Where is Biosergen AS headquartered?
Biosergen AS is based in Trondheim, Sor-Trondelag, Norway.
How many employees does Biosergen AS have?
Biosergen AS is in the 1-10 employee band.
How does Biosergen AS' funding compare to other Biotechnology startups?
Biosergen AS' latest round of $4.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Biosergen AS Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Biosergen AS is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.